bluebird bio Inc. (BLUE)
NASDAQ: BLUE
· Real-Time Price · USD
3.71
0.02 (0.54%)
At close: May 08, 2025, 3:59 PM
3.72
0.13%
After-hours: May 08, 2025, 06:43 PM EDT
0.54% (1D)
| Bid | 3.65 |
| Market Cap | 36.37M |
| Revenue (ttm) | 83.81M |
| Net Income (ttm) | -240.72M |
| EPS (ttm) | -24.84 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | -1.41 |
| Analyst | Hold |
| Ask | 3.72 |
| Volume | 110,021 |
| Avg. Volume (20D) | 412,514 |
| Open | 3.76 |
| Previous Close | 3.69 |
| Day's Range | 3.68 - 3.82 |
| 52-Week Range | 3.56 - 28.60 |
| Beta | 0.33 |
About BLUE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BLUE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BLUE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-7.16%
Carlyle Group and Bluebird Bio shares are trading ...
Unlock content with
Pro Subscription
1 month ago
+19.61%
BlueBird Bio shares are trading higher after the company received a non-binding written takeover proposal from Ayrmid. Also, Barclays maintained its Overweight rating on the stock.
1 month ago · accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bluebird Bio, Inc. - BLUENEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
1 month ago · accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUENEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
